These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19898280)

  • 1. Interpreting the results of the COURAGE trial: a non-interventionalist perspective.
    Boden WE
    Rev Cardiovasc Med; 2009; 10 Suppl 2():S34-44. PubMed ID: 19898280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial.
    Kereiakes DJ
    Rev Cardiovasc Med; 2009; 10 Suppl 2():S45-52. PubMed ID: 19898281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina.
    Latib A; Chieffo A; Colombo A
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):92-3. PubMed ID: 19065124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One year perspective on COURAGE.
    Tommaso CL
    Catheter Cardiovasc Interv; 2008 Sep; 72(3):426-429. PubMed ID: 18727125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
    Borden WB; Redberg RF; Mushlin AI; Dai D; Kaltenbach LA; Spertus JA
    JAMA; 2011 May; 305(18):1882-9. PubMed ID: 21558519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.
    Soares A; Boden WE; Hueb W; Brooks MM; Vlachos HEA; O'Fee K; Hardi A; Brown DL
    J Am Heart Assoc; 2021 Jan; 10(2):e019114. PubMed ID: 33442990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Mancini GBJ; Boden WE; Brooks MM; Vlachos H; Chaitman BR; Frye R; Bittner V; Hartigan PM; Dagenais GR
    Atherosclerosis; 2018 Oct; 277():186-194. PubMed ID: 29861270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Spertus JA; Maron DJ; Cohen DJ; Kolm P; Hartigan P; Weintraub WS; Berman DS; Teo KK; Shaw LJ; Sedlis SP; Knudtson M; Aslan M; Dada M; Boden WE; Mancini GB;
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):409-18. PubMed ID: 23838107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).
    Sedlis SP; Jurkovitz CT; Hartigan PM; Kolm P; Goldfarb DS; Lorin JD; Dada M; Maron DJ; Spertus JA; Mancini GB; Teo KK; Boden WE; Weintraub WS;
    Am J Cardiol; 2013 Dec; 112(11):1703-8. PubMed ID: 24011740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: One year perspective on COURAGE.
    Sedlis SP; Boden WE; Weintraub WS; Maron DS; O'Rourke RA; Berman DS; Mancini GB;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):428. PubMed ID: 19133682
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Maron DJ; Spertus JA; Mancini GB; Hartigan PM; Sedlis SP; Bates ER; Kostuk WJ; Dada M; Berman DS; Shaw LJ; Chaitman BR; Teo KK; O'Rourke RA; Weintraub WS; Boden WE;
    Am J Cardiol; 2009 Oct; 104(8):1055-62. PubMed ID: 19801024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of the BARI 2D and COURAGE trials: overview.
    Brooks MM; Boden WE; Frye RL
    Coron Artery Dis; 2010 Nov; 21(7):383-5. PubMed ID: 20664331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.
    Pursnani S; Korley F; Gopaul R; Kanade P; Chandra N; Shaw RE; Bangalore S
    Circ Cardiovasc Interv; 2012 Aug; 5(4):476-90. PubMed ID: 22872053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should percutaneous revascularization for stable coronary artery disease be performed sooner or later?
    Prasad A; Gersh BJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):480-2. PubMed ID: 19463348
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.
    Acharjee S; Teo KK; Jacobs AK; Hartigan PM; Barn K; Gosselin G; Tanguay JF; Maron DJ; Kostuk WJ; Chaitman BR; Mancini GB; Spertus JA; Dada MR; Bates ER; Booth DC; Weintraub WS; O'Rourke RA; Boden WE;
    Am Heart J; 2016 Mar; 173():108-17. PubMed ID: 26920603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum.
    Epstein SE; Waksman R; Pichard AD; Kent KM; Panza JA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):993-8. PubMed ID: 24156960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study.
    Nishigaki K; Yamazaki T; Kitabatake A; Yamaguchi T; Kanmatsuse K; Kodama I; Takekoshi N; Tomoike H; Hori M; Matsuzaki M; Takeshita A; Shimbo T; Fujiwara H;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):469-79. PubMed ID: 19463347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
    Holper EM; Addo T
    Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.